CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

The human B-cell marker CD19 is highly expressed in many non–Hodgkin's lymphomas and leukemias, and therefore offer an appealing immunotherapeutic target for cancers of lymphoid origin [1]. Anti-CD...